user

Pan-Canadian review of cancer drugs will not be binding on provinces

被引：3
|
作者：
Vogel, Lauren
机构：
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2010年 / 182卷 / 09期
关键词：
D O I：
10.1503/cmaj.109-3262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：887 / 888
页数：2
相关论文
共 50 条
  • [41] The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison
    Skedgel, C.
    CURRENT ONCOLOGY, 2016, 23 (05) : 322 - 328
  • [42] Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding
    Srikanthan, A.
    Mai, H.
    Penner, N.
    Amir, E.
    Laupacis, A.
    Sabharwal, M.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2017, 24 (05) : 295 - 301
  • [43] Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations
    Trudeau, M.
    Hoskins, P.
    Reiman, T.
    Chambers, A.
    Mai, H.
    Wheatley-Price, P.
    CURRENT ONCOLOGY, 2017, 24 (02) : 71 - 74
  • [44] Research, Practice, and Policy Partnerships in Pan-Canadian Coalitions for Cancer and Chronic Disease Prevention
    Manafo, Elizabeth
    Petermann, Lisa
    Lobb, Rebecca
    Keen, Deb
    Kerner, Jon
    JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE, 2011, 17 (06): : E1 - E11
  • [45] PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium
    Bosse, Dominick
    Mercer, Jamison
    Raissouni, Soundouss
    Dennis, Kristopher
    Goodwin, Rachel Anne
    Jiang, Maria
    Powell, Erin Diana
    Kumar, Aalok
    Lee-Ying, Richard M.
    Hiller, Julie A. Price
    Heng, Daniel Yick Chin
    Tang, Patricia A.
    MacLean, Anthony
    Cheung, Winson Y.
    Vickers, Michael M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] THE MANAGEMENT OF SMALL CELL LUNG CANCER WITH RADIOTHERAPY - A PAN-CANADIAN SURVEY OF RADIATION ONCOLOGISTS
    Shahi, Jeevin
    Wright, James
    Gabos, Zsolt
    Swaminath, Anand
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S87 - S87
  • [47] Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs
    Saluja, Ronak
    Jiao, Tina
    Koshy, Liza
    Cheung, Matthew
    Chan, Kelvin K. W.
    CURRENT ONCOLOGY, 2021, 28 (01) : 606 - 618
  • [48] POSITIVE CANCER DRUG RECOMMENDATIONS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW ARE NOT WITHOUT CONDITIONS PLACED ON COST-EFFECTIVENESS
    Grima, A.
    Whitney, S.
    Samjoo, I
    Grima, D.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
  • [49] Recommendations for the safe use and handling of oral anticancer drugs in community pharmacy: A pan-Canadian consensus guideline
    Vu, Kathy
    Emberley, Philip
    Brown, Erika
    Abbott, Rick
    Bates, Justin J.
    Bourrier, Venetia
    Djordjevic, Kathryn
    Greenall, Julie
    Leung, Mova
    Pasetka, Mark
    Paquet, Louise
    Logan, Heather
    CANADIAN PHARMACISTS JOURNAL, 2018, 151 (04) : 240 - 253
  • [50] Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
    Adam J. N. Raymakers
    Kristina M. Jenei
    Dean A. Regier
    Michael M. Burgess
    Stuart J. Peacock
    PharmacoEconomics, 2021, 39 : 373 - 377
12345